ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Pulmonary homograft dysfunction after the Ross procedure using decellularized homografts—a multicenter study

Saturday, April 9, 2022

Submitted by

Jessica Luc

Source

Source Name: Journal of Thoracic and Cardiovascular Surgery

Source URL: https://www.jtcvs.org/article/S0022-5223(20)32194-2/fulltext

Author(s)

Vincent Chauvette, MD, Ismail Bouhout, MD, Mohammed Tarabzoni, MD, Magali Pham, MD, Daniel Wong, MD, Richard Whitlock, MD, PhD, Michael W.A. Chu, MD, MSc, Ismail El-Hamamsy, MD, PhD, on behalf of the Canadian Ross Registry

This study from the Canadian Ross Registry evaluated 466 consecutive patients who underwent a Ross procedure using a decellularized cryopreserved pulmonary homograft and evaluated for pulmonary homograft dysfunction. They demonstrate that the cumulative incidence of pulmonary homograft dysfunction was 11% at 6 years with pulmonary homograft stenosis (93%) being the most frequent cause, with an incidence of homograft reintervention of 3% at 6 years.